Activating Mutations in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhance Reactive Oxygen Species Production That Contributes to Myeloproliferative Disorder

被引:26
|
作者
Xu, Dan [1 ]
Zheng, Hong [1 ]
Yu, Wen-Mei [1 ]
Qu, Cheng-Kui [1 ]
机构
[1] Case Western Reserve Univ, Dept Med, Ctr Stem Cell & Regenerat Med, Div Hematol & Oncol,Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
来源
PLOS ONE | 2013年 / 8卷 / 05期
基金
美国国家卫生研究院;
关键词
OF-FUNCTION MUTATION; GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC STEM; MOUSE MODEL; LEUKEMIA; BINDING; GENE; MITOCHONDRIA; CHECKPOINT; DISTINCT;
D O I
10.1371/journal.pone.0063152
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Gain of function (GOF) mutations in protein tyrosine phosphatase Ptpn11 have been identified in childhood leukemias, and these mutations are sufficient to drive the development of myeloproliferative disorder and malignant leukemias in mice. However, the molecular mechanisms by which Ptpn11 mutations induce these malignancies are not completely understood. Here we report that Ptpn11 GOF mutations cause cytokine hypersensitivity in hematopoietic cells partly by enhancing the production of reactive oxygen species (ROS). GOF mutations D61G or E76K in Ptpn11 increased ROS levels in myeloid progenitors but not in hematopoietic stem cells. Increased ROS enhanced cellular responses to cytokines by promoting cytokine signaling. Treatment with an antioxidant partially corrected cytokine hypersensitivity in Ptpn11 mutant progenitors. Further analyses demonstrated that Ptpn11 mutations increased mitochondrial aerobic metabolism by interacting with a novel substrate in the mitochondria. This study provides new insights into the pathogenic effects of GOF mutations of Ptpn11 and implies that antioxidants may have a therapeutic benefit for the leukemic patients with these mutations.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] The tyrosine phosphatase Shp2 (PTPN11) in cancer
    Chan, Gordon
    Kalaitzidis, Demetrios
    Neel, Benjamin G.
    CANCER AND METASTASIS REVIEWS, 2008, 27 (02) : 179 - 192
  • [2] The tyrosine phosphatase Shp2 (PTPN11) in cancer
    Gordon Chan
    Demetrios Kalaitzidis
    Benjamin G. Neel
    Cancer and Metastasis Reviews, 2008, 27 : 179 - 192
  • [3] Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11)
    Liu, Wei
    Yu, Bing
    Xu, Gang
    Xu, Wei-Ren
    Loh, Mignon L.
    Tang, Li-Da
    Qu, Cheng-Kui
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (18) : 7212 - 7221
  • [4] Protein Tyrosine Phosphatase Shp2 (Ptpn11) Plays an Important Role in Maintenance of Chromosome Stability
    Liu, Xia
    Zheng, Hong
    Qu, Cheng-Kui
    CANCER RESEARCH, 2012, 72 (20) : 5296 - 5306
  • [5] Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
    Tartaglia, M
    Mehler, EL
    Goldberg, R
    Zampino, G
    Brunner, HG
    Kremer, H
    van der Burgt, I
    Crosby, AH
    Ion, A
    Jeffery, S
    Kalidas, K
    Patton, MA
    Kucherlapati, RS
    Gelb, BD
    NATURE GENETICS, 2001, 29 (04) : 465 - 468
  • [6] Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis.
    Loh, ML
    Vattikuti, S
    Schubbert, S
    Reynolds, MG
    Carlson, E
    Lieuw, KH
    Cheng, JW
    Lee, CM
    Stokoe, D
    Bonifas, JM
    Curtiss, NP
    Emanuel, PD
    Shannon, KM
    BLOOD, 2003, 102 (11) : 108A - 108A
  • [7] Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
    Marco Tartaglia
    Ernest L. Mehler
    Rosalie Goldberg
    Giuseppe Zampino
    Han G. Brunner
    Hannie Kremer
    Ineke van der Burgt
    Andrew H. Crosby
    Andra Ion
    Steve Jeffery
    Kamini Kalidas
    Michael A. Patton
    Raju S. Kucherlapati
    Bruce D. Gelb
    Nature Genetics, 2001, 29 : 465 - 468
  • [8] Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis
    Li S.
    Hsu D.D.
    Wang H.
    Feng G.-S.
    Frontiers of Medicine, 2012, 6 (3) : 275 - 279
  • [9] PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects
    Kontaridis, MI
    Swanson, KD
    David, FS
    Barford, D
    Neel, BG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (10) : 6785 - 6792